Perinatal Survival Following Parvovirus B19 Infection: Overall Outcomes and a Secondary Comparison of the 2023–2024 Outbreak to the Previous Two Decades
Prenatal Diagnosis · 2025
DOI: 10.1002/pd.6860 ↗At a glance
Vergleichsstudie in Prenatal Diagnosis, 2025. Written by Noam Regev and 9 co-authors. Institution: Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel. Major MEDLINE topics: Parvovirus B19, Human, Pregnancy Complications, Infectious, Disease Outbreaks, Parvoviridae Infections. 25 references.
Abstract (original language)
Objectives
To evaluate perinatal survival following maternal parvovirus B19 virus (B19V) infection and compare the 2023–2024 outbreak to prior decades.
Method
A single tertiary center retrospective study (2005–2024) of all pregnancies with confirmed maternal B19V infection. Data on maternal, fetal, and neonatal outcomes were collected, with live birth rate as the primary outcome. Patients were divided into the 2023–2024 outbreak group and a control group (2005–2022) for comparison.
Results
Among 124 patients, 51 comprised the outbreak group and 73 comprised the control group. The live birth rate was 90.3%. Fetal hydrops (OR 18.0, 95% CI 2.12–153.03), intra‐uterine transfusion (IUT) requirement (OR 1.33, 95% CI 1.09–1.69) and an earlier gestational age at first IUT (OR 0.6, 95% CI 0.37–0.96) were associated with decreased perinatal survival. The outbreak group presented earlier (15.5 [IQR 10.2–20.4] vs. 19.5 [IQR 15.0–23.0], p = 0.04), and had a higher fetal viral load (cycle threshold value 11.5 [IQR 7.54–13.57] vs. 16.63 [IQR 13.42–20.59], p = 0.01). However, rates of hydrops, indication for IUT, perinatal survival, abnormal CNS findings, and neonatal outcomes did not differ between the groups.
Conclusions
Fetal hydrops and an earlier indication for IUT were predictors of IUFD. Despite earlier presentation and higher viral load, the outbreak did not worsen perinatal outcomes.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel.
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Clinical Virology Laboratory, Sheba Medical Center, Tel Hashomer, Israel.
ORCID profiles: Noam Regev, Yoav Yinon
Cite
APA
Regev, N., Pardo, N., Axelrod, M., Berkovitz, C., Klapholz, E., Mor, O., Avnet, H., Weisz, B., Mazaki-Tovi, S., & Yinon, Y. (2025). Perinatal Survival Following Parvovirus B19 Infection: Overall Outcomes and a Secondary Comparison of the 2023–2024 Outbreak to the Previous Two Decades. Prenatal Diagnosis. https://doi.org/10.1002/pd.6860
Vancouver
Regev N, Pardo N, Axelrod M, Berkovitz C, Klapholz E, Mor O, et al. Perinatal Survival Following Parvovirus B19 Infection: Overall Outcomes and a Secondary Comparison of the 2023–2024 Outbreak to the Previous Two Decades. Prenatal Diagnosis. 2025. doi:10.1002/pd.6860
BibTeX
@article{Regev2025,
author = {Regev, Noam and Pardo, Noam and Axelrod, Michal and Berkovitz, Chen and Klapholz, Eliel and Mor, Orna and Avnet, Hagai and Weisz, Boaz and Mazaki-Tovi, Shali and Yinon, Yoav},
title = {Perinatal Survival Following Parvovirus B19 Infection: Overall Outcomes and a Secondary Comparison of the 2023–2024 Outbreak to the Previous Two Decades},
journal = {Prenatal Diagnosis},
year = {2025},
doi = {10.1002/pd.6860}
}
EUVIMED